Nano Holdings, Inc. (TYO:4571)

Market Cap	9.19B -3.6%
Revenue (ttm)	174.00M +61.1%
Net Income	-943.00M
EPS	-12.89
Shares Out	82.76M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	588,300
Open	110.00
Previous Close	111.00
Day's Range	108.00 - 112.00
52-Week Range	103.00 - 254.00
Beta	0.36
Analysts	n/a
Price Target	n/a
Earnings Date	May 15, 2026

About Nano Holdings

Nano Holdings, Inc. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company’s pipeline products include RUNX1 (mRNA) for the treatment knee osteoarthritis and reduces pain; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma multiforme. In addition, it offers cosmetic raw material. The company was formerly known as NANO MRNA Co.,Ltd. and changed its name to Nano Holdings,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 20
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4571

Financial Performance

In fiscal year 2026, Nano Holdings's revenue was 174.00 million, an increase of 61.11% compared to the previous year's 108.00 million. Losses were -943.00 million, 12.9% more than in 2025.